MarketCap
Facebook
X
Telegram
Lineage Cell Therapeutics Income Statement 2025-2008 | LCTX
Brief overview of income trends at Lineage Cell Therapeutics
The figures are compared over a five-year interval. The revenue attributed to Lineage Cell Therapeutics moved from 1.8 million dollars to 14.6 million dollars between the two endpoints. The five-year change reached +697.2%, while CAGR stood at 51.5%. This pace points to rapid expansion of the business.
The five-year EBITDA result moved by −47.6%: from −24.3 million dollars to −35.9 million dollars. EBITDA lagged revenue, showing weaker operating momentum. EBITDA margin was −1332.7% at the start and −246.8% at the end. Higher profitability strengthens the quality of operating growth.
Across the five years, the net result shifted from −20.6 million dollars to −63.5 million dollars. The period ended with a larger loss than it began with.
Market value was 331 million dollars at the start and 421 million dollars at the end. Investors responded cautiously to the improvement in the business.
Conclusion
The figures do not all move in the same direction. Key strengths include a larger revenue base and higher operating efficiency. The main areas of concern are limited operating profitability and declining net profitability. The key question is whether sales can be converted into sustainable profit.
Annual Income Statement Lineage Cell Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
421 M | 366 M | 192 M | 243 M | 232 M | 331 M | 156 M | 180 M | 339 M | 294 M | 193 M | 271 M | 209 M | 222 M | 279 M | 199 M | - | - |
Shares |
230 M | 200 M | 173 M | 170 M | 165 M | 150 M | 146 M | 127 M | 114 M | 97.3 M | 79.7 M | 66.5 M | 54.2 M | 49.2 M | 47.5 M | 40.3 M | - | - |
Historical Prices |
1.83 | 1.83 | 1.11 | 1.43 | 1.41 | 2.3 | 1.01 | 1.2 | 2.62 | 3.25 | 2.3 | 4.2 | 3.59 | 4.21 | 4.99 | 4.93 | 2.17 | 0.484 |
Net Income |
-63.5 M | -18.6 M | -21.5 M | -6.35 M | -29 M | -20.6 M | -11.7 M | -46 M | -20 M | 33.6 M | -47 M | -36.4 M | -43.9 M | -21.4 M | -16.5 M | -11.2 M | -5.14 M | - |
Revenue |
14.6 M | 9.5 M | 8.94 M | 1.92 M | 1.17 M | 1.83 M | 3.52 M | 4.99 M | 3.46 M | 5.92 M | 7.04 M | 5.24 M | 4.43 M | 3.92 M | 4.35 M | 3.71 M | - | - |
Cost of Revenue |
- | 334 K | 671 K | 728 K | 1.43 M | 385 K | 412 K | 302 K | 168 K | 358 K | 1.11 M | 837 K | 793 K | 434 K | 79.4 K | 27.7 K | - | - |
Gross Profit |
- | - | 8.27 M | 14 M | 2.92 M | 1.44 M | 3.1 M | 4.69 M | 3.29 M | 5.56 M | 5.93 M | 4.41 M | 3.64 M | 3.48 M | 4.35 M | 3.68 M | - | - |
Operating Income |
-36.6 M | -21.5 M | -24.7 M | -6.64 M | -28.2 M | -26.4 M | -38.9 M | -41.8 M | -38.9 M | -59 M | -65.8 M | -50.7 M | -56 M | -25 M | -18.7 M | -9.85 M | -3.52 M | - |
Interest Expense |
-132 K | -670 K | 542 K | -2.15 M | 1.49 M | 2.88 M | 2.53 M | -1.7 M | 1.45 M | -403 K | -160 K | -384 K | -204 K | 19.4 K | 29.7 K | -124 K | -1.65 M | - |
EBITDA |
-35.9 M | -20.9 M | -24.2 M | -6.06 M | -27.6 M | -24.3 M | -35.7 M | -37.7 M | -37.4 M | -54.2 M | -59.5 M | -42.3 M | -34.6 M | -22.2 M | -16.3 M | -9.71 M | -3.49 M | - |
Operating Expenses |
- | - | 8.19 M | 8.45 M | 29.2 M | 27.9 M | 42 M | 45.7 M | 43.9 M | 64.5 M | 71.7 M | 55.1 M | 42.2 M | 28.5 M | 23 M | 13.5 M | 5.45 M | - |
General and Administrative Expenses |
18.5 M | 18.2 M | 17.3 M | 22.5 M | 18.2 M | 15.6 M | 24 M | 24.7 M | 19.9 M | 28.4 M | 29.1 M | 17.6 M | 15.6 M | 10.4 M | - | 5.34 M | -2.26 M | - |
All numbers in USD currency
Quarterly Income Statement Lineage Cell Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
249 M | 245 M | 229 M | 228 M | 226 M | 220 M | 189 M | 189 M | 183 M | 175 M | 175 M | 171 M | 170 M | 170 M | 170 M | 170 M | 170 M | 169 M | 168 M | 163 M | 159 K | 153 M | 150 M | 150 K | 150 M | 150 M | 150 M | 150 M | 133 M | 127 M | 127 M | 127 M | 127 M | 127 M | 115 M | 111 M | 107 K | 103 M | 103 K | 93.2 K | 90.4 K | 90.4 M | 79.2 K | 78.4 K | 78.3 M | 78.2 M | 67.9 M | 61.5 M | 58.3 M | 56.7 M | 55.6 M | 53.8 M | 51.2 M | 49.4 M | 49.3 M | 50.5 M | 49 M | 49 M | 48.9 M | 48.8 M | 49 M |
Net Income |
1.48 M | -4.81 M | -29.8 M | -30.5 M | -4.14 M | - | -3.03 M | -5.76 M | -6.54 M | - | -7.11 M | -5.23 M | -4.37 M | - | -6.07 M | -6.76 M | -7.09 M | -29 M | -7.82 M | -4.8 M | -1.45 M | 2.03 M | -7.76 M | -6.52 M | -8.4 M | -4.48 M | -16.5 M | -30 M | 39.3 M | -45 M | 66.7 M | -4.22 M | -63.5 M | -71.9 M | 14.3 M | -11.7 M | 49.3 M | -4.94 M | 31.2 M | 24.5 M | -17.1 M | -13.5 M | -13.6 M | -9.69 M | -10.2 M | -10.6 M | -8.27 M | -9.52 M | -8.1 M | -19.6 M | -9 M | -7.55 M | -7.72 M | -6.04 M | -4.96 M | -5.46 M | -4.97 M | -5.14 M | -3.74 M | -4.28 M | -3.36 M |
Revenue |
1.07 M | 1.72 M | 3.68 M | 2.76 M | 1.5 M | - | 3.78 M | 1.41 M | 1.44 M | - | 1.25 M | 3.22 M | 2.39 M | - | 3 M | 4.55 M | 5.24 M | 1.17 M | 2.27 M | 512 K | 391 K | 355 K | 571 K | 386 K | 514 K | 1.24 M | 567 K | 779 K | 928 K | 758 K | 982 K | 2.55 M | 701 K | 945 K | 1.64 M | 376 K | 390 K | 1.1 M | 1.5 M | 1.27 M | 2.07 M | 1.31 M | 2.31 M | 2.01 M | 1.26 M | 1.66 M | 1.19 M | 1.11 M | 1.07 M | 1.67 M | 714 K | 1.22 M | 614 K | 1.07 M | 1 M | 1.03 M | 652 K | 1.63 M | 1.14 M | 756 K | 825 K |
Cost of Revenue |
- | - | - | - | 36 K | - | 38 K | 44 K | 98 K | - | 169 K | 127 K | 119 K | - | 235 K | 215 K | 176 K | - | 985 K | 125 K | 112 K | - | 102 K | 75 K | 94 K | - | 114 K | 107 K | 68 K | - | 35 K | 106 K | 109 K | - | 52 K | 5 K | 57 K | - | 58 K | 95 K | 225 K | - | 432 K | 260 K | 264 K | - | 231 K | 252 K | 132 K | - | 207 K | 181 K | 183 K | - | 170 K | 83.9 K | 20.3 K | - | 18.5 K | 24.8 K | - |
Gross Profit |
- | - | - | - | - | - | - | - | - | - | 1.08 M | 3.1 M | 2.27 M | - | 2.76 M | 4.34 M | 5.06 M | - | 1.28 M | 387 K | 279 K | - | 469 K | 311 K | 420 K | - | 453 K | 672 K | 860 K | - | 947 K | 2.44 M | 592 K | - | 1.64 M | 376 K | 333 K | - | 1.44 M | 1.17 M | 1.85 M | - | 1.87 M | 1.75 M | 1 M | - | 960 K | 855 K | 935 K | - | 507 K | 1.04 M | 432 K | - | 834 K | 950 K | 632 K | - | 1.14 M | 756 K | - |
Operating Income |
-8.92 M | -7.59 M | -3.79 M | -19.8 M | -6.5 M | - | -3.84 M | -5.87 M | -6.66 M | - | -6.7 M | -5.02 M | -6.64 M | - | -5.25 M | -4.23 M | -6.4 M | -28.2 M | -6.84 M | -7.08 M | -7.05 M | -5.88 M | -6.72 M | -6.4 M | -7.44 M | -6.87 M | -8.42 M | -10.8 M | -12.8 M | -10.1 M | -10.4 M | -9.14 M | -12.2 M | -9.56 M | -9.51 M | -8.56 M | -11.3 M | -11.3 M | -9.56 M | -14.4 M | -23.8 M | -21.7 M | -17.1 M | -13.5 M | -13.5 M | -14.4 M | -12.1 M | -13.1 M | -11.1 M | -29.3 M | -10.2 M | -8.12 M | -8.38 M | -7.06 M | -5.95 M | -6.08 M | -5.92 M | -5.45 M | -4.23 M | -4.98 M | -4.03 M |
Interest Expense |
-18 K | 1 K | - | 26 K | -185 K | - | - | 19 K | - | - | 1 K | 86 K | 457 K | - | -475 K | -1.89 M | -184 K | - | 393 K | 970 K | -1.68 M | - | 351 K | 1.17 M | -1.35 M | - | 582 K | 882 K | 806 K | - | -7 K | -839 K | -176 K | - | -143 K | 617 K | 727 K | - | -173 K | 237 K | 128 K | - | -573 K | 225 K | -240 K | - | -119 K | -10 K | -8.38 K | - | 509 | 579 | 943 | - | 22.9 K | 85.1 K | 8.3 K | - | -4.25 K | -19.3 K | 13.2 K |
EBITDA |
-8.74 M | -7.4 M | -3.61 M | -19.6 M | -6.34 M | - | -3.7 M | -5.72 M | -6.51 M | - | -6.56 M | -4.89 M | -6.5 M | - | 140 M | 142 M | -6.25 M | -28.2 M | -6.34 M | -6.74 M | -6.88 M | -5.88 M | -6.52 M | -6.19 M | -7.23 M | -6.87 M | -8.17 M | -10.6 M | -12.5 M | -10.1 M | -10.1 M | -8.86 M | -11.9 M | -9.56 M | -9.26 M | -8.36 M | -11 M | -11.3 M | -8.56 M | -13.7 M | -23.3 M | -21.7 M | -16.3 M | -13 M | -13.2 M | -14.4 M | -11.3 M | -12.5 M | -10.9 M | -29.3 M | -9.78 M | -8 M | -8.27 M | -7.06 M | -5.66 M | -5.99 M | -5.83 M | -5.45 M | -3.97 M | -4.85 M | -3.96 M |
Operating Expenses |
- | - | - | - | - | - | - | - | - | - | 7.78 M | 8.12 M | 8.91 M | - | 8.01 M | 8.57 M | 11.5 M | 29.2 M | 8.13 M | 7.47 M | 7.33 M | 6.12 M | 7.19 M | 6.71 M | 7.86 M | 7.99 M | 8.88 M | 11.5 M | 13.6 M | 10.8 M | 11.3 M | 11.6 M | 12.8 M | 10.5 M | 11.1 M | 10.7 M | 11.6 M | 12.4 M | 11 M | 15.6 M | 25.6 M | 23 M | 19 M | 15.2 M | 14.5 M | 16.1 M | 13.1 M | 13.9 M | 12.1 M | 13.5 M | 10.7 M | 9.15 M | 8.81 M | 8.12 M | 6.78 M | 7.03 M | 6.55 M | 7.08 M | 5.38 M | 5.74 M | 4.85 M |
General and Administrative Expenses |
5.22 M | 5.08 M | 4.19 M | 4.56 M | 4.86 M | - | 4.41 M | 4.36 M | 5 M | - | 4.04 M | 4.25 M | 4.72 M | - | 4.42 M | 5.27 M | 8.47 M | - | 5.32 M | 4.54 M | 3.94 M | - | 3.63 M | 3.91 M | 4.52 M | - | 4.61 M | 6.26 M | 8.66 M | - | 6.42 M | 5.23 M | 6.04 M | - | 4.59 M | 4.42 M | 5.1 M | - | 4.57 M | 6.64 M | 11.9 M | - | 7.54 M | 6.19 M | 5.18 M | - | 4.26 M | 4.84 M | 3.67 M | - | 4.27 M | 3.62 M | 3.42 M | - | 2.23 M | 2.41 M | 2.37 M | - | 1.89 M | 2.4 M | 1.9 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Lineage Cell Therapeutics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Canada
China
France
Germany
Israel
Britain
Russia
Belgium
Cayman-islands
